{"id":"W4392739578","doi":"10.1038/s41467-024-46495-2","title":"PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer","year":2024,"lang":"en","type":"article","venue":"Nature Communications","topic":"Cancer-related gene regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":43,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Susan G. Komen; Cancer Prevention and Research Institute of Texas; Welch Foundation; National Cancer Institute; U.S. Department of Health and Human Services; Breast Cancer Research Foundation; U.S. Department of Defense","keywords":"Protein arginine methyltransferase 5; Cancer research; Fulvestrant; Retinoblastoma protein; Breast cancer; Downregulation and upregulation; Palbociclib; Biology; Estrogen receptor; Cancer; Cell cycle; Methyltransferase; Metastatic breast cancer; Biochemistry; Genetics","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001467107,0.000248827,0.0001945559,0.0001788659,0.0001441206,0.0002931148,0.0002215027,0.0002886139,0.001163883],"category_scores_gemma":[0.00009943347,0.0001315318,0.000177877,0.0001392579,0.0001728756,0.0001586013,0.0001692482,0.0003861233,0.0004259087],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004743788,"about_ca_system_score_gemma":0.0002524177,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004696663,"about_ca_topic_score_gemma":0.0008443858,"domain_scores_codex":[0.9998919,0.00001089576,0.000006400218,0.00002190874,0.00004876997,0.00002009683],"domain_scores_gemma":[0.9999589,0.000004638235,0.00001672077,0.000005113013,0.000004639332,0.00001000942],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0001276544,0.00002264111,0.0004072853,0.00007493971,0.000006563514,0.0001001047,0.00001023563,0.0003613349,0.989781,0.0004889627,0.0003535315,0.00826567],"study_design_scores_gemma":[0.00002889056,0.0003563607,0.003784614,0.00001045363,0.00002458536,0.0009142461,0.00001577437,0.001735341,0.9762577,0.0001776271,0.01668875,0.000005728909],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9579318,0.01800091,0.01156052,0.001328813,0.0001490541,0.00007166124,0.000902162,0.0007062965,0.00934876],"genre_scores_gemma":[0.9875398,0.00439222,0.003117958,0.0001382117,0.00001866404,0.00002138615,0.0006217969,0.00003053751,0.004119433],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001163883,"threshold_uncertainty_score":0.003893554,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01314758869348883,"score_gpt":0.3076607452952672,"score_spread":0.2945131566017783,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}